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ABSTRACT
YKL-40 is a glycoprotein with pro-angiogenic functions. We hypothesized that 
patients with newly diagnosed glioblastoma and low baseline plasma YKL-40 levels 
derive greater benefit from first-line bevacizumab. Plasma samples were collected 
from 563 patients in the randomized, phase 3 AVAglio trial who received bevacizumab 
or placebo plus radiotherapy/temozolomide. Raw plasma YKL-40 concentrations 
were converted to age-corrected percentiles of normal healthy YKL-40 levels and 
divided into quartiles (Q). The impact of baseline plasma YKL-40 level on survival was 
investigated using Cox regression analyses. Patients with low baseline plasma YKL-40 
(≤Q1) had an improved progression-free survival hazard ratio (HR) for bevacizumab 
versus placebo (0.37, 95% confidence interval [CI]: 0.25–0.55) compared with 
high plasma YKL-40 (> Q1) (0.71, 95% CI: 0.57–0.87). Overall survival HRs were 
comparable between the subgroups (≤ Q1: 0.69, 95% CI: 0.44–1.09; (> Q1: 0.88, 
95% CI: 0.68–1.13). A trend for improved progression-free survival HR with low 
versus high YKL-40 was observed in proneural glioblastoma (0.41, 95% CI: 0.13–1.28 
vs 0.80, 95% CI: 0.45–1.40, respectively), but not for proliferative/mesenchymal 
subtypes. Elevated plasma YKL-40 (> 90th percentile of normal) was an independent 
negative prognostic factor. In conclusion, the predictive value of baseline plasma 
YKL-40 level as a biomarker for bevacizumab efficacy in glioblastoma may be limited 
to patients with proneural tumors. Independent validation studies are required to 
confirm these results.
INTRODUCTION
CHI3L1 (Chitinase-3-like protein 1) is one of the 
most overexpressed genes in glioblastomas, relative to 
normal brain and low-grade gliomas [1]. CHI3L1 is a 
marker for the mesenchymal subtype of glioblastoma and 
is related to extracellular-signal-regulated kinases and 
protein kinase B phosphorylation [2]. YKL-40, which is 
encoded by the CHI3L1 gene, is produced by tumor cells, 
inflammatory cells, and stem cells [3–5]. YKL-40 interacts 
with the receptors IL-13Rα2 [6], CRTH2 [7], RAGE [8], 
syndecan-1 [9], and PAR-2 [10], but its function is not 
completely known. YKL-40 induces vascular endothelial 
growth factor (VEGF) expression and both YKL-40 and 
VEGF are pro-angiogenic factors associated with tumor 
angiogenesis [11–17]. In vitro, YKL-40 up-regulates 
VEGF in the U87 human glioblastoma cell line, and 
long-term inhibition of VEGF induces expression of 
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YKL-40 (potentially as a compensatory response, i.e. 
‘angiogenic rebound’) [9, 11–17]. Surprisingly, shRNA 
knockdown of YKL-40 in tumor-derived mural-like cells 
(GSDCs) also increased VEGF expression and secretion 
[18]. These apparently contradictory results could be 
explained by tumor heterogeneity and cell diversity, 
different models with varying YKL-40 and VEGF 
expression, and a compensatory increase in VEGF as a 
result of long-term YKL-40 blockade in shRNA YKL-
40 cells [18]. Irradiation of U87 cells increases YKL-40 
expression [12, 19] and inhibition of YKL-40 enhances 
U87 cell death in response to irradiation [9]. In vivo, 
inhibition of YKL-40 in xenografted mice decreases 
angiogenesis, tumor formation, and metastasis in various 
tumor models [9, 12]. Of note, the expression of VEGF 
and YKL-40 are correlated in both xenografted mice and 
human glioblastoma samples [12]. Combination therapy 
with irradiation and anti-YKL-40 neutralizing antibody 
in xenografted glioblastoma tumor models resulted in 
decreased tumor growth, reduced tumor vascularization, 
and increased survival compared with monotherapy [14]. 
YKL-40 mRNA and protein expression increase 
with glioma grade and are higher in glioblastoma than 
in astrocytic- and oligodendroglial tumors [1, 2, 19–28]. 
In patients with glioblastoma, high YKL-40 expression 
in glioma cells is associated with poor response 
to radiotherapy (RT) and a shorter time to disease 
progression and death [14–17, 20, 21, 28]. YKL-40 is 
part of a 9-gene paraffin tissue-based expression panel 
that predicts survival in patients with glioblastoma [29]. 
Patients with epidermal growth factor receptor (EGFR) 
variant III-negative/YKL-40-negative tumors have a better 
prognosis than other tumor subtypes [25, 30]. It has also 
been shown that YKL-40 silencing in glioblastoma cells 
impairs proliferation, neurosphere formation, and their 
ability to induce endothelial cell migration [31].  
In 55% to 75% of patients with glioblastoma, 
plasma YKL-40 is elevated compared with healthy 
subjects [32–34]. Iwamoto et al. showed that serum YKL-
40 is lower in patients with glioblastoma and anaplastic 
gliomas without radiographic disease versus those with 
radiographic disease [33]. An increase in serum YKL-
40 after surgery was also independently associated with 
short survival times in patients with glioblastoma or newly 
diagnosed anaplastic glioma [34]. 
Bevacizumab is a humanized monoclonal antibody 
directed against VEGF-A. Bevacizumab is often used 
as salvage therapy for patients with glioblastoma, 
either as monotherapy or in combination with different 
chemotherapy regimens [35]. A substantial proportion 
of patients appear to benefit from bevacizumab in 
this setting, and identifying this patient subgroup is an 
unmet need to date. In the AVAglio study, patients with 
newly diagnosed glioblastoma treated with RT and 
temozolomide (TMZ) in combination with bevacizumab 
had improved progression-free survival (PFS), but not 
overall survival (OS), compared with patients treated with 
RT/TMZ and placebo [36]. A similarly designed study 
confirmed the lack of OS benefit for bevacizumab in the 
first-line setting [37].
Objective response to bevacizumab has been 
correlated with improved OS in the recurrent setting 
[38], indicating that specific subgroups of patients may 
obtain a survival benefit from bevacizumab. Finding 
biomarkers that may identify patients eligible for 
bevacizumab treatment is therefore highly relevant. 
Based on the hypothesis that YKL-40 levels in blood 
and tumor correlate, and that low YKL-40 enhances the 
effect of bevacizumab (VEGF neutralization), we tested 
the hypothesis that patients in AVAglio with low YKL-40 
plasma concentrations will derive a greater benefit from 
bevacizumab than patients with higher YKL-40 plasma 
concentrations, due to the proposed interaction between 
VEGF, YKL-40, and tumor angiogenesis [11–18].
RESULTS
The biomarker-evaluable population comprised 
279 patients treated with bevacizumab plus RT/TMZ and 
284 patients treated with placebo plus RT/TMZ. Patient 
characteristics were comparable between the biomarker-
evaluable and intent-to-treat (ITT) populations (Table 1). 
The first quartile (Q1), median, and third quartile (Q3) of 
raw plasma YKL-40 levels at baseline were 39 ng/mL, 65 
ng/mL, and 109 ng/mL, respectively. The corresponding 
values for age-corrected percentile of normal plasma 
YKL-40 were 29th, 59th, and 89th percentiles. Raw- and 
age-corrected levels of plasma YKL-40 in the placebo 
compared with the bevacizumab cohort at baseline were: 
median 70 ng/mL versus 60 ng/mL (p = 0.02), and median 
percentile 70th versus 59th (p = 0.02), respectively.
Baseline plasma YKL-40 and patient 
characteristics
Baseline plasma YKL-40 levels were higher in 
patients with poor World Health Organization (WHO) 
performance status (PS) and in patients who did not have 
a complete tumor resection (Table 2). Baseline plasma 
YKL-40 did not differ significantly between molecular 
subtypes.
Elevated baseline plasma YKL-40 and prognosis
Fifty-six patients (10%) had elevated plasma YKL-
40 (> 90th percentile of normal) at baseline, which was 
an independent predictor of shorter PFS and OS (Table 
3). The estimated impact of elevated baseline YKL-
40 (PFS hazard ratio [HR] 1.84 and OS HR 1.94) was 
comparable to the impact of poor WHO PS and non-
methylated O-6-methylguanine-DNA methyltransferase 
gene promoter.
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Baseline plasma YKL-40 and bevacizumab 
efficacy
Bevacizumab was associated with longer PFS in 
patients with baseline plasma YKL-40 both below and above 
the lowest quartile (Q1). The PFS HR was improved in 
patients with baseline plasma YKL-40 below Q1 (Table 4), 
relative to the PFS benefit seen for patients with higher 
baseline plasma YKL-40. The PFS HR was 0.37 (95% 
confidence interval [CI]: 0.25–0.55) for patients with YKL-
40 levels ≤ Q1, and 0.71 (95% CI: 0.57–0.87) for patients 
with YKL-40 levels > Q1. The OS HR was comparable 
between the subgroups, with overlapping CIs: OS HR was 
0.69 (95% CI: 0.44–1.09) for patients with YKL-40 levels 
≤ Q1 and 0.88 (95% CI: 0.68–1.13) for patients with YKL-
40 levels > Q1. The PFS and OS Kaplan-Meier curves 
according to YKL-40 level ≤ Q1 versus > Q1 are shown in 
Figure 1. In a multivariate analysis with correction for other 
baseline characteristics, the interaction between YKL-40 
level with Q1 as cut off and bevacizumab treatment was not 
significant (p = 0.24 for PFS and p = 0.32 for OS).
 When all samples were combined, the relative 
change in plasma YKL-40 level from baseline to second 
cycle, or from baseline to the end of combination 
treatment, was not correlated with bevacizumab efficacy 
(Supplementary Figure 1, available online only).
Table 1: Comparison of clinical and biomarker-evaluable cohorts
Total trial 
Cohort (n = 921), n (%)
Biomarker-evaluable
Cohort (n = 563), n (%) pa
Gender 0.91
 Female 341 (37) 206 (37)
 Male 580 (63) 357 (63)
Age 0.85
 ≤ 65 years 721 (78) 438 (78)
 > 65 years 200 (22) 125 (22)
Race 0.72
 Non-white 89 (10) 51 (9)
 White 832 (90) 512 (91)
WHO PS 0.20
 0 465 (50) 304 (54)
 1 455 (49) 258 (46)
MGMT gene promoter status 0.39
 Methylated 237 (26) 142 (25)
 Non-methylated 461 (50) 295 (52)
 Missing 223 (24) 126 (22)
Type of surgery 0.22
 Biopsy only 104 (11) 52 (9)
 Partial resection 433 (47) 284 (50)
 Complete resection 384 (42) 227 (40)
Corticosteroid use at baseline 0.63
 < 2 mg 522 (57) 327 (58)
 ≥2 mg 395 (43) 232 (41)
 Missing 4 (<1) 4 (< 1)
Smoking status 0.75
 Current smoker 120 (13) 65 (12)
 Never smoker 470 (51) 292 (52)
 Past smoker 330 (36) 205 (36)
aFisher’s exact test. Baseline characteristics with more than two levels were combined to compare the largest subgroup 
against all others.
MGMT = O-6-methylguanine-DNA methyltransferase.
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For patients with the proneural subtype of 
glioblastoma, there was a trend for improved PFS HR 
with low (cut off Q1) versus high plasma YKL-40 levels 
(> Q1), although CIs overlapped: PFS HR 0.41 (95% 
CI: 0.13–1.28) versus 0.80 (95% CI: 0.45–1.40). A less 
pronounced trend was noted for OS HR in patients with 
the proneural subtype of glioblastoma: HR 0.50 (95% CI: 
0.17–1.45) versus OS HR 0.69 (95% CI: 0.39–1.24), for 
≤ Q1 versus > Q1, respectively. No correlation between 
YKL-40 levels and bevacizumab efficacy was noted in 
patients with proliferative and mesenchymal glioblastoma 
subtypes (Table 5). The sample size for these calculations 
was very small, as evidenced by the wide CIs.
Plasma YKL-40 during treatment and at 
progression
Median plasma YKL-40 levels did not change 
greatly during treatment or follow up (Supplementary 
Figure 2, available online only) and no apparent difference 
was noted in temporal YKL-40 levels between the placebo 
and bevacizumab cohorts. However, plasma YKL-40 was 
numerically lower at the time of progression compared 
with baseline, although the difference was not extensive 
(Supplementary Figure 3, available online only).
DISCUSSION
To our knowledge, this is the first large prospective/
retrospective biomarker study to investigate the prognostic 
and predictive value of plasma YKL-40 in patients with 
glioblastoma who received bevacizumab. Based on 
evidence suggesting a pro-angiogenic role of YKL-40 and 
interaction with VEGF [18], we hypothesized that low 
levels of plasma YKL-40 could be predictive of greater 
clinical benefit from anti-VEGF treatment. Based on raw 
plasma concentrations of YKL-40 fitted to age-corrected 
percentiles using the established normal YKL-40 level in 
Figure 1: Kaplan-Meier survival curves for (A) progression-free survival and (B) overall survival, according to baseline plasma YKL-40 
levels.  BEV, bevacizumab; Plb, placebo; Q1, lowest quartile of plasma YKL-40 levels.
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healthy individuals [39], we report a greater numerical 
median PFS benefit with bevacizumab in patients with 
baseline plasma YKL-40 ≤ Q1 (below the 29th percentile 
of normal). We chose to divide the samples by quartiles 
of plasma YKL-40 levels instead of using a continuous 
scale because we did not expect the predictive value of 
plasma YKL-40 to be a continuous phenomenon. This was 
supported by the finding that patients with plasma YKL-
40 above Q3 had a HR for bevacizumab versus placebo 
that was very similar to the HR for patients with plasma 
YKL-40 between Q1 and the median.
Using Q1 as a cut off in the subset of patients with 
available molecular subtyping data, we saw the same trend 
for an improved PFS HR in patients with baseline plasma 
YKL-40 ≤ Q1, but only in patients with the proneural 
subtype of glioblastoma. Although the results of this 
subgroup analysis are based on a small number of patients, 
this finding is encouraging, since these patients may be the 
ones who derive most benefit from front-line bevacizumab 
[40]. 
The differences observed were larger for PFS than 
for OS, which may have been confounded by second-line 
cross-over to bevacizumab in the placebo group (common 
in this study) [36]. However, cross-over did not influence 
the magnitude of bevacizumab benefit in patients with 
the proneural subtype of glioblastoma. In the present 
analysis, molecular subclasses were defined according to 
Phillips et al. [24], but other classifications exist [2, 41] and 
Table 2: Baseline plasma YKL-40 and patient characteristics
 YKL-40, ng/mL YKL-40, percentilea
Median pb Median pb
Gender  0.40  0.28
   Female 62 64
   Male 67  67  
Age < 0.0001 0.07
   ≤ 65 years 57  64  
   > 65 years 98 73
Race  0.14  0.24
   Non-white 90 78
   White 64  64  
WHO PS < 0.0001 0.001
   0 53  56  
   1 78 73
Type of surgery  0.03  0.0496
   Biopsy only 65 64
   Partial resectionc 69  70  
   Complete resection 55 60
Smoking status  0.31  0.93
   Current smoker 57 60
   Never smoker 63  65  
   Past smoker 70 67
Molecular subtyped (n = 305) 0.49 0.41
   Proneural 67 61
   Mesenchymal 70 70
   Proliferative 61 63
aPercentile of YKL-40 according to the established normal YKL-40 level in healthy individuals [39]. 
bp value from Mann-Whitney U test for two groups or Kruskal-Wallis test for > 2 groups comparing biomarker levels across 
the groups.
cPartial resection meant that some extent of tumor debulking was undertaken but macroscopically visible tumor was left 
behind. This should be contrasted with either diagnostic biopsy only or removal of all visible tumor (complete resection). 
Since patients with partial resections have larger tumor burdens, higher levels of YKL-40 are to be expected.
dMolecular subtype as defined in the study by Philips et al. 2006 [24].
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different subtypes have been found within the same tumor. 
This intra- and inter-tumor heterogeneity in glioblastoma 
complicates the analysis of potential correlations between 
molecular subtype and biomarkers like YKL-40 [41] and 
a more advanced subtyping could strengthen the use of 
YKL-40 as a biomarker for bevacizumab response. YKL-
40 expression is a key feature of the mesenchymal glioma 
subtype and is also found in proneural tumors, where it has 
been located in tumor cells associated with blood vessels. In 
the description of the molecular sub-classification, Phillips 
et al. reported that eight of 26 matched tumors changed 
subtype at recurrence; seven of these to the mesenchymal 
subtype [24]. Depending on the significance of YKL-
40 leakage from tumor tissue to systemic circulation and 
intratumoral heterogeneity, our results could imply that 
patients with proneural tumors and low plasma YKL-40 
may have a better prognosis because neither systemic- nor 
tumor-related YKL-40 is affecting tumor growth or immune 
functions. To our knowledge, only Kazakova et al. [42] 
have described both tumor and serum YKL-40 in patients 
with glioblastoma (n = 14) and suggested that serum YKL-
40 correlated positively with tissue YKL-40 expression, 
although it was not clear how this analysis was performed. 
In patients with chemotherapy-refractory ovarian 
cancer treated with single-agent bevacizumab, low-to-
normal plasma YKL-40 at baseline was associated with 
longer PFS and OS suggesting that plasma YKL-40 could 
be a predictive biomarker for bevacizumab in several 
tumor types [43].
Ninety percent of patients had normal plasma YKL-
40 (< 90th percentile of normal) at baseline in the current 
study, which could be a reflection of the low tumor burden 
in these newly diagnosed patients. We validated the 
previously reported negative prognostic impact of having 
an elevated plasma YKL-40 at baseline. We did not find 
any predictive impact of change in plasma YKL-40 during 
treatment, but the power for this analysis was low.
Loss of blood-brain barrier integrity with 
ensuing changes in trans- and para-cellular transport 
is a characteristic associated with high-grade gliomas 
[44, 45] and is used to assess therapeutic response. In 
glioblastoma- and glioblastoma/oligodendroglioma-mouse 
models, weekly magnetic resonance imaging (MRI) 
scans showed increased blood-brain barrier disruption, 
which was incomplete only in the glioblastoma/
oligodendroglioma model [45]. It is possible that this 
heterogeneous breakdown of the blood-brain barrier in 
glioblastoma releases variable amounts of YKL-40 into 
the circulation, making it difficult to interpret plasma 
YKL-40 as a biomarker, compared with cancers outside 
Table 3: Elevated baseline plasma YKL-40 and prognosis - multivariate analysis
Progression-free survivala
HR 95% CI p
Treatment: BEV versus Plb 0.60 0.48–0.76 < 0.0001
YKL-40 level: elevated versus normalb 1.84 1.20–2.80 0.0047
Age, per year increase 1.02 1.00–1.03 0.018
Race: white versus non-white 1.61 1.12–2.32 0.011
WHO performance status: 0 versus 1 to 2 0.69 0.55–0.87 0.0013
MGMT: methylated versus non-methylated 0.47 0.37–0.61 < 0.0001
Type of surgery: biopsy versus complete/partial resection 0.45 0.25–0.79 0.0058
Overall survivala
HR 95% CI p
Treatment: BEV versus Plb 0.94 0.74–1.20 0.63
YKL-40 level: elevated versus normalb 1.94 1.23–3.06 0.0042
Age, per year increase 1.02 1.00–1.04 0.011
Race: white versus non-white 1.74 1.16–2.61 0.0076
WHO PS: 0 versus 1 to 2 0.66 0.52–0.84 0.0007
MGMT: methylated versus non-methylated 0.39 0.29–0.51 < 0.0001
Corticosteroid use at baseline: < 2 mg versus ≥ 2 mg 0.75 0.59–0.95 0.019
aOnly significant variables are shown. The following variables were included in the multivariate model but were not 
significantly associated with either endpoint: gender, Mini-Mental State Examination score, delay between surgery and 
subsequent treatment, primary versus secondary glioblastoma, enzyme-inducing anti-epileptic drug use at baseline, and 
confirmation of glioblastoma histology (yes/no).
bCut-off used for the definition of elevated plasma YKL-40 was the 90th percentile of normal [39].
BEV = bevacizumab; MGMT = O-6-methylguanine-DNA methyltransferase; Plb = placebo.
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the central nervous system. A comparison of contrast-
enhancement and perfusion on MRI and the corresponding 
plasma YKL-40 levels could further elucidate this subject. 
It would have been relevant to compare plasma YKL-40 
levels with tumor tissue YKL-40 expression, measured 
using immunohistochemistry, but we did not have access 
to tissue samples in this study.  
Among the strengths of this study was the large 
number of plasma samples collected (n = 563), although, 
some subgroup numbers were low. Furthermore, the 
samples were collected prospectively as part of a 
randomized, placebo-controlled trial and we tested a 
prespecified hypothesis that had a biologic rationale. 
Moreover, a trend for a predictive effect of plasma 
YKL-40 was seen only in the proneural molecular 
subtype, which has previously been suggested to derive 
most benefit from bevacizumab. Important limitations 
also exist; for example, the test for interaction between 
bevacizumab effect and baseline plasma YKL-40 with Q1 
as a cut off was not significant in the multivariate analysis. 
This would be expected if the effect of YKL-40 was 
isolated to a smaller subset of patients, e.g. the proneural 
subset. It also suggests that baseline plasma YKL-40 alone 
is not a strong enough biomarker to accurately predict 
bevacizumab benefit. Furthermore, we did not provide an 
independent validation of our findings, and even though 
Table 4: Baseline plasma YKL-40 level and bevacizumab efficacy
Progression-free survival
Plb + RT/TMZ BEV+ RT/TMZ
YKL-40 levela Patients, n Median, months Patients, n
Median, 
months HR 95% CI
≤ Q1 62 4.2 79 12.9 0.37 0.25–0.55
> Q1 to ≤ Median 70 6.5 71 10.0 0.63 0.44–0.91
> Median to ≤ Q3 71 7.8 70 10.2 0.85 0.58–1.24
> Q3 81 5.7 59 10.0 0.65 0.45–0.94
> Q1 222 6.1 200 10.0 0.71 0.57–0.87
Overall survival
Plb + RT/TMZ BEV+ RT/TMZ
YKL-40 levela Patients, n Median, months Patients, n
Median, 
months HR 95% CI
≤ Q1 62 16.6 79 19.1 0.69 0.44–1.09
> Q1 to ≤ Median 70 17.5 71 17.6 0.83 0.53–1.30
> Median to ≤ Q3 71 18.1 70 16.8 1.05 0.67–1.65
> Q3 81 13.4 59 15.4 0.85 0.56–1.29
> Q1 222 15.8 200 16.8 0.88 0.68–1.13
aPercentile of YKL-40 according to the established normal YKL-40 level in healthy individuals [39].
BEV = bevacizumab; Plb = placebo; Q1 to Q3 = first to third quartile of age-corrected YKL-40 levels.
Table 5: Baseline plasma YKL-40 and bevacizumab efficacy by molecular subtypea
Plasma YKL-40 levelb n PFS HR 95% CI OS HR 95% CI
Proneural
≤ Q1 21 0.41 0.13–1.28 0.50 0.17–1.45
> Q1 63 0.80 0.45–1.40 0.69 0.39–1.24
Proliferative
≤ Q1 20 0.56 0.21–1.51 1.05 0.40–2.72
> Q1 59 0.55 0.32–0.97 0.91 0.51–1.62
Mesenchymal
≤ Q1 36 0.58 0.27–1.23 1.01 0.47–2.20
> Q1 106 0.64 0.4–0.97 1.10 0.71–1.70
aMolecular subtype as defined in the study by Philips et al. 2006 [24].
bPercentile of YKL-40 according to the established normal YKL-40 level in healthy individuals [39].
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we prespecified a hypothesis about low plasma YKL-40 
levels predicting a greater bevacizumab benefit, we did 
not lock a cut-off point before undertaking the study.
In conclusion, these results represent an encouraging 
first foray into the use of plasma YKL-40 as a biomarker 
in patients with glioblastoma treated with bevacizumab. 
Further studies are needed to investigate plasma YKL-40 
in patients with cancer given an anti-angiogenic agent, to 
validate the positive predictive effect of low-to-normal 
plasma YKL-40 levels, and to determine the optimal cut-off 
point. It would also be of interest to investigate the double-
inhibition of VEGF and YKL-40 for the treatment of cancer.
MATERIALS AND METHODS
Ethics statement
The protocol was approved by the applicable 
independent ethics committees and institutional review 
boards. All clinical investigations were conducted according 
to the principles expressed in the Declaration of Helsinki 
and according to national and international guidelines and 
were approved by the authors’ institutional review board. 
All patients provided written informed consent.
Patients
AVAglio was a randomized, double-blind, placebo-
controlled trial (NCT00943826; https://clinicaltrials.gov/
ct2/show/NCT00943826) [36]. Full methods, including 
patient randomization, treatment, and follow-up, are 
published [36]. Patients with newly diagnosed glioblastoma 
received bevacizumab or placebo in combination with 
standard post-surgical RT/TMZ. Eligibility criteria included 
a WHO PS of ≤ 2, adequate healing of the operation site, 
and preserved organ function. Patients were excluded if 
they had a recent symptomatic intracranial hemorrhage, 
prior brain RT, prior glioblastoma treatment, recent 
intracranial abscess, or a serious non-healing wound. After 
surgical resection or biopsy, patients received RT consisting 
of 2-Gy fractions 5 days per week for 6 weeks, concurrent 
with daily oral TMZ (75 mg/m2), in combination with 
intravenous bevacizumab (10 mg/kg) or placebo every 2 
weeks. Following RT/TMZ and a 4-week treatment break, 
patients received maintenance treatment with TMZ (150 
mg/m2/day on days 1 to 5 during the first 4-week cycle and 
200 mg/m2/day on days 1 to 5 during the following cycles) 
and intravenous bevacizumab (10 mg/kg) or placebo every 
14 days for six 4-week cycles. Subsequently, patients 
without progression were treated with bevacizumab (15 
mg/kg) or placebo as monotherapy every 3 weeks until 
progression or unacceptable toxicity [36]. 
The determination of progression was based 
on a combination of MRI, clinical assessment, and 
corticosteroid use, as previously described [36]. Co-
primary endpoints were PFS, defined as time from 
randomization to progression or death from any cause, 
and OS, defined as time from randomization to death 
from any cause.
Blood sampling and plasma YKL-40 analysis
The first plasma sample (baseline) was drawn within 
29 to 48 days after surgery and before treatment with 
RT/TMZ and bevacizumab/placebo. Thereafter, plasma 
samples were drawn at regular intervals during treatment 
and at the time of disease progression.
Blood samples were centrifuged within 2 hours at 
3,000 × g for 10 minutes at room temperature. Plasma was 
transferred into cryotubes and stored at –80°C. Plasma 
concentration of YKL-40 was determined in duplicate 
using a commercial enzyme-linked immunosorbent assay 
(Quidel, San Diego, California). The detection limit was 
20 ng/mL, the intra-assay coefficient of variation (CV) was 
< 5%, and the inter-assay CV was < 6% [39, 46]. Plasma 
YKL-40 was determined at the Department of Medicine, 
Herlev University Hospital, Denmark and investigators 
were blinded to the treatment arms and clinical data. 
The reference intervals for plasma YKL-40 were 
determined in 3,130 healthy subjects (1,837 women, 
1,293 men) aged 21 to 84 years from the Danish general 
population (part of the Copenhagen City Heart Study) 
[39]. These subjects had no known disease at the time of 
blood sampling from 1991 to 1994, and remained healthy 
and alive during the 16-year follow-up period. The median 
plasma YKL-40 concentration in these 3,130 healthy 
subjects was 40 ng/mL.
Molecular subtypes of glioblastoma
Three molecular subtypes of glioblastoma have 
been identified by gene expression analysis: proneural, 
proliferative, and mesenchymal [24]. Using tumor samples 
from the AVAglio trial, Sandmann et al. found that the 
molecular subtype of glioblastoma could be predictive 
for bevacizumab efficacy [40]. Therefore, data regarding 
molecular subtypes were included in our analyses. 
Statistical analysis
Raw plasma concentrations of YKL-40 were 
transformed to age-corrected percentiles using the 
established normal YKL-40 level in healthy individuals 
[39]. All YKL-40 levels referred to are percentiles of 
normal level unless explicitly called ‘raw’. Comparisons 
were made between quartiles of YKL-40 levels (> Q1 vs ≤ 
Q1); and between normal (≤ 90th percentile) and elevated 
(> 90th percentile) YKL-40 levels. The selection of Q1 as 
a cut off was supported by the plot shown Supplementary 
Figure 4 (available online only).
Fisher’s exact test was used to compare baseline 
characteristics between the biomarker evaluable 
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population and the ITT population. The Mann-Whitney 
U test (for two groups) or Kruskal-Wallis test (for > 2 
groups) was used to compare YKL-40 levels by baseline 
patient characteristics. Kaplan-Meier methodology was 
applied for time-to-event endpoints. The associations 
between plasma YKL-40 level and PFS and OS were 
tested using univariate and multivariate Cox regression. 
All results were reported in accordance with REMARK 
guidelines [47]. 
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